In multivariable analysis, the molecular subtype was independently associated with OS: compared with HER2−/HR+ tumours, hazard ratios were 0.90 (95% CI: 0.80–1.02, p < 0.0001), 0.63 (95% CI: 0.55–0.71, p < 0.0001) and 1.87 (95% CI: 1.70–2.06, p < 0.0001) for HER2+/HR−, HER2+/RH+ and triple-negative tumours, respectively. Here, ERBB2 is linked to neoplasm.